Jutta Stoffers-Winterling1, Annegret Krause-Utz2, Klaus Lieb1, Martin Bohus3,4. 1. Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Mainz, Mainz, Deutschland. 2. Abteilung für Klinische Psychologie, Leiden Institute of Brain and Cognitio, AK Leiden, Universität Leiden, Leiden, Niederlande. 3. Institut für Psychiatrische und Psychosomatische Psychotherapie, Lehrstuhl für Psychosomatische Medizin und Psychotherapie, Medizinische Fakultät Mannheim, Universität Heidelberg, Zentralinstitut für Seelische Gesundheit Mannheim, J 5, 68159, Mannheim, Deutschland. martin.bohus@zi-mannheim.de. 4. Harvard Medical School, Boston, USA. martin.bohus@zi-mannheim.de.
Abstract
BACKGROUND: Borderline personality disorder (BPS) is considered as a severe mental disorder with a high burden for patients, family members and the healthcare system. Recent years have brought significant advances in understanding and treating BP, leading to an earlier diagnosis and better treatment outcomes. OBJECTIVE: This article outlines the current state of knowledge on the epidemiology, diagnostics, psychopathology and treatment of BPD and identifies open questions. MATERIAL AND METHODS: Based on a literature search in the PubMed, PsycINFO and EMBASE databases, the latest developments in the topic of BPD for the areas of diagnostics, epidemiology, etiology and treatment are illuminated in a narrative review. Where possible systematic review articles, meta-analyses and evidence-based practice guidelines were also considered. STATE OF THE SCIENCE: At the core of BPS are disorders of emotion regulation, self-image, and interpersonal interaction. The suicide rates range from 2% to 5% and life expectancy is significantly shortened compared with the general population. The effectiveness of differentiated, disorder-specific psychotherapy (especially dialectic behavioral therapy, DBT) is well established. Psychotherapeutic care in the outpatient sector, especially in the field of pediatric and adolescent psychiatry, is still insufficient. PERSPECTIVES: Questions about the etiopathology, especially genetic and postulated neurobiological parameters that determine affective hypersensitivity, are largely open. Nosologically, the differentiation from comorbid complex posttraumatic stress disorder (cPTSD) is certainly an important issue, which also has therapeutic consequences.
BACKGROUND: Borderline personality disorder (BPS) is considered as a severe mental disorder with a high burden for patients, family members and the healthcare system. Recent years have brought significant advances in understanding and treating BP, leading to an earlier diagnosis and better treatment outcomes. OBJECTIVE: This article outlines the current state of knowledge on the epidemiology, diagnostics, psychopathology and treatment of BPD and identifies open questions. MATERIAL AND METHODS: Based on a literature search in the PubMed, PsycINFO and EMBASE databases, the latest developments in the topic of BPD for the areas of diagnostics, epidemiology, etiology and treatment are illuminated in a narrative review. Where possible systematic review articles, meta-analyses and evidence-based practice guidelines were also considered. STATE OF THE SCIENCE: At the core of BPS are disorders of emotion regulation, self-image, and interpersonal interaction. The suicide rates range from 2% to 5% and life expectancy is significantly shortened compared with the general population. The effectiveness of differentiated, disorder-specific psychotherapy (especially dialectic behavioral therapy, DBT) is well established. Psychotherapeutic care in the outpatient sector, especially in the field of pediatric and adolescent psychiatry, is still insufficient. PERSPECTIVES: Questions about the etiopathology, especially genetic and postulated neurobiological parameters that determine affective hypersensitivity, are largely open. Nosologically, the differentiation from comorbid complex posttraumatic stress disorder (cPTSD) is certainly an important issue, which also has therapeutic consequences.
Authors: Lars Schulze; Andreas Schulze; Babette Renneberg; Christian Schmahl; Inga Niedtfeld Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2018-11-16
Authors: Lisa Liebke; Melanie Bungert; Janine Thome; Sophie Hauschild; Dorothee Maria Gescher; Christian Schmahl; Martin Bohus; Stefanie Lis Journal: Personal Disord Date: 2016-08-08
Authors: Christina M Temes; Frances R Frankenburg; Garrett M Fitzmaurice; Mary C Zanarini Journal: J Clin Psychiatry Date: 2019-01-22 Impact factor: 4.384
Authors: Mie Sedoc Jørgensen; Ole Jakob Storebø; Jutta M Stoffers-Winterling; Erlend Faltinsen; Adnan Todorovac; Erik Simonsen Journal: PLoS One Date: 2021-01-14 Impact factor: 3.240
Authors: Charlotte Skoglund; Annika Tiger; Christian Rück; Predrag Petrovic; Philip Asherson; Clara Hellner; David Mataix-Cols; Ralf Kuja-Halkola Journal: Mol Psychiatry Date: 2019-06-03 Impact factor: 15.992
Authors: Martin Bohus; Nikolaus Kleindienst; Christopher Hahn; Meike Müller-Engelmann; Petra Ludäscher; Regina Steil; Thomas Fydrich; Christine Kuehner; Patricia A Resick; Christian Stiglmayr; Christian Schmahl; Kathlen Priebe Journal: JAMA Psychiatry Date: 2020-12-01 Impact factor: 21.596